Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (31-40 of 300) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Immunotherapy for Hematologic MalignanciesCharles Craddock, Jonathan W Friedberg
Oncology (Williston Park, N.Y.)|November 29, 2013
Management of marginal zone lymphomaRobin Reid, Jonathan W Friedberg
Best Practice & Research. Clinical Haematology|September 15, 2018
Burkitt lymphoma- a rare but challenging lymphomaCarla Casulo, Jonathan W Friedberg
Oncology (Williston Park, N.Y.)|July 25, 2009
Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapiesRohit Sud, Jonathan W Friedberg
Haematologica|December 4, 2008
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximabRohit Sud, Jonathan W Friedberg
The Oncologist|October 8, 2003
PET scans in the staging of lymphoma: current statusJonathan W Friedberg, Vaseem Chengazi
Hematological Oncology|June 8, 2017
Chemotherapy free treatment of indolent lymphomaCarla Casulo, Jonathan W Friedberg
Current Hematologic Malignancy Reports|April 29, 2010
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphomaManzurul A Sikder, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 29, 2008
Diffuse large B-cell lymphomaJonathan W Friedberg, Richard I Fisher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2025
Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO TrialDanielle S Wallace, Jonathan W Friedberg
Pageof 30

Showing results (31-40 of 300) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Immunotherapy for Hematologic MalignanciesCharles Craddock, Jonathan W Friedberg
Oncology (Williston Park, N.Y.)|November 29, 2013
Management of marginal zone lymphomaRobin Reid, Jonathan W Friedberg
Best Practice & Research. Clinical Haematology|September 15, 2018
Burkitt lymphoma- a rare but challenging lymphomaCarla Casulo, Jonathan W Friedberg
Oncology (Williston Park, N.Y.)|July 25, 2009
Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapiesRohit Sud, Jonathan W Friedberg
Haematologica|December 4, 2008
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximabRohit Sud, Jonathan W Friedberg
The Oncologist|October 8, 2003
PET scans in the staging of lymphoma: current statusJonathan W Friedberg, Vaseem Chengazi
Hematological Oncology|June 8, 2017
Chemotherapy free treatment of indolent lymphomaCarla Casulo, Jonathan W Friedberg
Current Hematologic Malignancy Reports|April 29, 2010
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphomaManzurul A Sikder, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 29, 2008
Diffuse large B-cell lymphomaJonathan W Friedberg, Richard I Fisher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2025
Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO TrialDanielle S Wallace, Jonathan W Friedberg
Pageof 30